Fertility potential in patients with ovarian cancer

Abstract

Malignant neoplasms of the reproductive system are the most common form of oncological morbidity in women, accounting for over 30% of all cancer cases. Most antineoplastic agents act by inducing DNA damage in highly proliferating cancer cells, resulting in oocyte death. Ovarian toxicity is the most common side effect of cancer treatment in young women. Both chemotherapy and radiotherapy have been shown to be toxic to the ovaries, increasing the risk of premature ovarian failure, early menopause, endocrine disorders, and infertility. Patients who have undergone cancer treatment have severe follicular atresia, even if they have a regular menstrual cycle.

Currently, the most effective methods of preserving fertility in cancer patients include cryopreservation of oocytes and embryos after ovarian hyperstimulation. Other fertility preservation methods include ovarian tissue cryopreservation, follicle or embryo maturation in vitro, ovarian transposition, ovarian suppression, and adjuvant therapy.

Despite promising fertility prospects, iatrogenic infertility is one of the most undesirable adverse effects of cancer therapy for young women. Timely referral to a gynecologist prior to chemotherapy or radiation therapy is key to successful fertility preservation. Women should be aware of the available opportunities of assisted reproductive technologies, along with potential risks and failures with regard to their age, stage of disease, and treatment method. At this stage, it is necessary to develop well-defined and effective algorithms for oncologists, obstetrician-gynecologists, fertility specialists, and embryologists.

Keywords

literature review / oncofertility / ovarian cancer / breast cancer / iatrogenic infertility / premature ovarian failure / ovarian tissue cryopreservation / oocytes and embryo cryopreservation

References

[1] Kaprin AD, Starinskij VV, Shahzаdova AO, editors. The state of oncological care for the population of Russia in 2021. Moscow: P.A. Herzen Institute of Oncology — branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russian Federation; 2022. (In Russ.)

[2] Состояние онкологической помощи населению России в 2021 году / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2022.

[3] Kaprin AD, Starinskij VV, Shahzаdova AO, editors. The state of oncological care for the population of Russia in 2021. Moscow: P.A. Herzen Institute of Oncology — branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russian Federation; 2022. (In Russ.)

[4] Viale PH. The American cancer society’s facts & figures. J Adv Pract Oncol. 2020;11(2):135–136. doi: 10.6004/jadpro.2020.11.2.1

[5] Viale P.H. The American cancer society’s facts & figures // J Adv Pract Oncol. 2020. Vol. 11, N 2. P. 135–136. doi: 10.6004/jadpro.2020.11.2.1

[6] Viale PH. The American cancer society’s facts & figures. J Adv Pract Oncol. 2020;11(2):135–136. doi: 10.6004/jadpro.2020.11.2.1

[7] The Oncofertility Consortium [cited 2024 March 25]. Available from: https://oncofertility.msu.edu/about/dr-teresa-k-woodruff-phd

[8] The Oncofertility Consortium. Режим доступа: https://oncofertility.msu.edu/about/dr-teresa-k-woodruff-phd Дата обращения: 25.03.2024.

[9] The Oncofertility Consortium [cited 2024 March 25]. Available from: https://oncofertility.msu.edu/about/dr-teresa-k-woodruff-phd

[10] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. Published online April 5, 2021. doi: 10.1002/ijc.33588

[11] Ferlay J., Colombet M., Soerjomataram I., et al. Cancer statistics for the year 2020: An overview // Int J Cancer. Published online April 5, 2021. doi: 10.1002/ijc.33588

[12] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. Published online April 5, 2021. doi: 10.1002/ijc.33588

[13] Salama M, Woodruff TK. Anticancer treatments and female fertility: clinical concerns and role of oncologists in oncofertility practice. Expert Review of Anticancer Therapy. 2017;17(8):687–692. doi: 10.1080/ 14737140.2017.1335199

[14] Salama M., Woodruff T.K. Anticancer treatments and female fertility: clinical concerns and role of oncologists in oncofertility practice // Expert Review of Anticancer Therapy. 2017. Vol. 17, N 8. P. 687–692. doi: 10.1080/ 14737140.2017.1335199

[15] Salama M, Woodruff TK. Anticancer treatments and female fertility: clinical concerns and role of oncologists in oncofertility practice. Expert Review of Anticancer Therapy. 2017;17(8):687–692. doi: 10.1080/ 14737140.2017.1335199

[16] Goldman KN, Chenette D, Arju R, et al. mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy. Proc Natl Acad Sci USA. 2017;114(12):3186–3191. doi: 10.1073/pnas.1617233114

[17] Goldman K.N., Chenette D., Arju R., et al. mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy // Proc Natl Acad Sci USA. 2017. Vol. 114, N 12. P. 3186–3191. doi: 10.1073/pnas.1617233114

[18] Goldman KN, Chenette D, Arju R, et al. mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy. Proc Natl Acad Sci USA. 2017;114(12):3186–3191. doi: 10.1073/pnas.1617233114

[19] Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673–693. doi: 10.1093/humupd/dmz027

[20] Spears N., Lopes F., Stefansdottir A., et al. Ovarian damage from chemotherapy and current approaches to its protection // Hum Reprod Update. 2019. Vol. 25, N 6. P. 673–693. doi: 10.1093/humupd/dmz027

[21] Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673–693. doi: 10.1093/humupd/dmz027

[22] Vartanyan EV, Dobrohotova YuE, Devyatova EA, Tsaturova KA. Females’ fertility preservation in malignancies. Russian Journal of Human Reproduction. 2020;26(4):68–76. EDN: ZBSOJH doi: 10.17116/repro20202604168

[23] Вартанян Э.В., Доброхотова Ю.Э., Девятова Е.А., Цатурова К.А. Сохранение женской фертильности при онкологических заболеваниях // Проблемы репродукции. 2020. Т. 26, № 4. С. 68–76. EDN: ZBSOJH doi: 10.17116/repro20202604168

[24] Vartanyan EV, Dobrohotova YuE, Devyatova EA, Tsaturova KA. Females’ fertility preservation in malignancies. Russian Journal of Human Reproduction. 2020;26(4):68–76. EDN: ZBSOJH doi: 10.17116/repro20202604168

[25] Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention World Cancer Reports. 2020.

[26] Wild C.P., Weiderpass E., Stewart B.W., editors. World Cancer Report: Cancer Research for Cancer Prevention World Cancer Reports. 2020.

[27] Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention World Cancer Reports. 2020.

[28] Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz Men opauzalny. 2023;22(2):93–104. doi: 10.5114/pm.2023.128661

[29] Ali A.T., Al-Ani O., Al-Ani F. Epidemiology and risk factors for ovarian cancer // Prz Men opauzalny. 2023;22(2):93–104. doi: 10.5114/pm.2023.128661

[30] Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz Men opauzalny. 2023;22(2):93–104. doi: 10.5114/pm.2023.128661

[31] Trabert B, Tworoger SS, O’Brien KM, et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the ovarian cancer cohort consortium (OC3). Cancer Res. 2020;80(5):1210–1218. doi: 10.1158/0008-5472.CAN-19-2850

[32] Trabert B., Tworoger S.S., O’Brien K.M., et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the ovarian cancer cohort consortium (OC3) // Cancer Res. 2020. Vol. 80, N 5. P. 1210–1218. doi: 10.1158/0008-5472.CAN-19-2850

[33] Trabert B, Tworoger SS, O’Brien KM, et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the ovarian cancer cohort consortium (OC3). Cancer Res. 2020;80(5):1210–1218. doi: 10.1158/0008-5472.CAN-19-2850

[34] Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888–2898. doi: 10.1200/JCO.2016.66.8178

[35] Wentzensen N., Poole E.M., Trabert B., et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium // J Clin Oncol. 2016. Vol. 34, N 24. P. 2888–2898. doi: 10.1200/JCO.2016.66.8178

[36] Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888–2898. doi: 10.1200/JCO.2016.66.8178

[37] Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;57(4):957–958.

[38] Narod S., Ford D., Devilee P., et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium // Am J Hum Genet. 1995. Vol. 57, N 4. P. 957–958.

[39] Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;57(4):957–958.

[40] Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute. 2013;105(11):812–822. doi: 10.1093/jnci/djt095

[41] Mavaddat N., Peock S., Frost D., et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE // Journal of the National Cancer Institute. 2013. Vol. 105, N 11. P. 812–822. doi: 10.1093/jnci/djt095

[42] Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute. 2013;105(11):812–822. doi: 10.1093/jnci/djt095

[43] Nodin B, Zendehrokh N, Sundstrom M, Jirstrom K. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagnostic pathology. 2013;8:106. doi: 10.1186/1746-1596-8-106

[44] Nodin B., Zendehrokh N., Sundstrom M., Jirstrom K. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer // Diagnostic pathology. 2013. Vol. 8. P. 106. doi: 10.1186/1746-1596-8-106

[45] Nodin B, Zendehrokh N, Sundstrom M, Jirstrom K. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagnostic pathology. 2013;8:106. doi: 10.1186/1746-1596-8-106

[46] Li K, Husing A, Fortner RT, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. British Journal of Cancer. 2015;112(7):1257–1265. doi: 10.1038/bjc.2015.22

[47] Li K., Husing A., Fortner R.T., et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study // British journal of cancer. 2015. Vol. 112, N 7. P. 1257–1265. doi: 10.1038/bjc.2015.22

[48] Li K, Husing A, Fortner RT, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. British Journal of Cancer. 2015;112(7):1257–1265. doi: 10.1038/bjc.2015.22

[49] Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clinical Endocrinology. 1998;49(6):695–707. doi: 10.1046/j.1365-2265.1998.00577.x

[50] Riman T., Persson I., Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence // Clinical Endocrinology. 1998. Vol. 49, N 6. P. 695–707. doi: 10.1046/j.1365-2265.1998.00577.x

[51] Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clinical Endocrinology. 1998;49(6):695–707. doi: 10.1046/j.1365-2265.1998.00577.x

[52] Zou J, Li Y, Liao N, et al. Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis. J Ovarian Res. 2022;15(1):30. doi: 10.1186/s13048-022-00962-w

[53] Zou J., Li Y., Liao N., et al. Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis // J Ovarian Res. 2022. Vol. 15, N 1. P. 30. doi: 10.1186/s13048-022-00962-w

[54] Zou J, Li Y, Liao N, et al. Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis. J Ovarian Res. 2022;15(1):30. doi: 10.1186/s13048-022-00962-w

[55] Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer epidemiology, biomarkers & prevention. 2005;14(1):98–107.

[56] Lukanova A., Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses // Cancer epidemiology, biomarkers & prevention. 2005. Vol. 14, N 1. P. 98–107.

[57] Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer epidemiology, biomarkers & prevention. 2005;14(1):98–107.

[58] Li AJ, Elmore RG, Pavelka JC, Karlan BY. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecologic Oncology. 2007;107(3):420–423. doi: 10.1016/j.ygyno.2007.07.059

[59] Li A.J., Elmore R.G., Pavelka J.C., Karlan B.Y. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology // Gynecologic Oncology. 2007. Vol. 107, N 3. P. 420–423. doi: 10.1016/j.ygyno.2007.07.059

[60] Li AJ, Elmore RG, Pavelka JC, Karlan BY. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecologic Oncology. 2007;107(3):420–423. doi: 10.1016/j.ygyno.2007.07.059

[61] Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009:472:413–437. doi: 10.1007/978-1-60327-492-0_20

[62] Permuth-Wey J., Sellers T.A. Epidemiology of ovarian cancer // Methods Mol Biol. 2009. Vol. 472. P. 413–437. doi: 10.1007/978-1-60327-492-0_20

[63] Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009:472:413–437. doi: 10.1007/978-1-60327-492-0_20

[64] Carnero A, Blanco-Aparicio C, Renner O., et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8(3):187–198. doi: 10.2174/156800908784293659

[65] Carnero A., Blanco-Aparicio C., Renner O., et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications // Curr Cancer Drug Targets. 2008. Vol. 8, N 3. P. 187–198. doi: 10.2174/ 156800908784293659

[66] Carnero A, Blanco-Aparicio C, Renner O., et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8(3):187–198. doi: 10.2174/156800908784293659

[67] McClam M, Xiao S. Preserving oocytes in oncofertility. Biology of Reproduction. 2022;106(2):328–337. doi: 10.1093/biolre/ioac008

[68] McClam M., Xiao S. Preserving oocytes in oncofertility // Biology of Reproduction. 2022. Vol. 106, N 2. P. 328–337. doi: 10.1093/biolre/ioac008

[69] McClam M, Xiao S. Preserving oocytes in oncofertility. Biology of Reproduction. 2022;106(2):328–337. doi: 10.1093/biolre/ioac008

[70] Alhmoud JF, Woolley JF, Moustafa AA, Malki MI. DNA damage/repair management in cancers. Cancers (Basel). 2020;12(4):1050. doi: 10.3390/cancers12041050

[71] Alhmoud J.F., Woolley J.F., Moustafa A.A., Malki M.I. DNA damage/repair management in cancers // Cancers (Basel). 2020. Vol. 12, N 4. P. 1050. doi: 10.3390/cancers12041050

[72] Alhmoud JF, Woolley JF, Moustafa AA, Malki MI. DNA damage/repair management in cancers. Cancers (Basel). 2020;12(4):1050. doi: 10.3390/cancers12041050

[73] Fries JF, Sharp GC, McDevitt HO, Holman HR. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum. 1973;16(2):154–162. doi: 10.1002/art.1780160204

[74] Fries J.F., Sharp G.C., McDevitt H.O., Holman H.R. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis // Arthritis Rheum. 1973. Vol. 16, N 2. P. 154–162. doi: 10.1002/art.1780160204

[75] Fries JF, Sharp GC, McDevitt HO, Holman HR. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum. 1973;16(2):154–162. doi: 10.1002/art.1780160204

[76] Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–1409. doi: 10.1002/1097-0142(197704)39:4<1403:aidcncr2820390408>3.0.co;2-8

[77] Koyama H., Wada T., Nishizawa Y., et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer // Cancer. 1977. Vol. 39, N 4. P. 1403–1409. doi: 10.1002/1097-0142(197704)39:4<1403:aidccr2820390408>3.0.co;2-8

[78] Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–1409. doi: 10.1002/1097-0142(197704)39:4<1403:aidcncr2820390408>3.0.co;2-8

[79] Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62. doi: 10.1126/scitranslmed.3005402

[80] Kalich-Philosoph L., Roness H., Carmely A., et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility // Sci Transl Med. 2013. Vol. 5, N 185. P. 185ra62. doi: 10.1126/scitranslmed.3005402

[81] Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62. doi: 10.1126/scitranslmed.3005402

[82] Volochayeva MV, Shmakov RG, Demina YeA. Influence of chemotherapy on reproductive system: methods of protection and preservation of ovarian function. Clinical Oncohematology. 2014;7(2):114–118. EDN: SZHALD

[83] Волочаева М.В., Шмаков Р.Г., Демина Е.А. Влияние противоопухолевого лечения на репродуктивную систему женщин: методы защиты и сохранения функции яичников // Клиническая онкогематология. 2014. Т. 7, № 2. С. 114–118. EDN: SZHALD

[84] Volochayeva MV, Shmakov RG, Demina YeA. Influence of chemotherapy on reproductive system: methods of protection and preservation of ovarian function. Clinical Oncohematology. 2014;7(2):114–118. EDN: SZHALD

[85] Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. doi: 10.1200/JCO.2018.78.1914

[86] Oktay K., Harvey B.E., Partridge A.H., et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update // J Clin Oncol. 2018. Vol. 36, N 19. P. 1994–2001. doi: 10.1200/ JCO.2018.78.1914

[87] Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. doi: 10.1200/JCO.2018.78.1914

[88] Marci R, Mallozzi M, Di Benedetto L, et al. Radiations and female fertility. Reprod Biol Endocrinol. 2018;16(1):112. doi: 10.1186/s12958-018-0432-0

[89] Marci R., Mallozzi M., Di Benedetto L., et al. Radiations and female fertility // Reprod Biol Endocrinol. 2018. Vol. 16, N 1. P. 112. doi: 10.1186/s12958-018-0432-0

[90] Marci R, Mallozzi M, Di Benedetto L, et al. Radiations and female fertility. Reprod Biol Endocrinol. 2018;16(1):112. doi: 10.1186/s12958-018-0432-0

[91] Gracia C, Woodruff TK. Oncofertility medical practice: Clinical issues and implementation. New York: Springer; 2012. doi: 10.1007/978-1-4419-9425-7

[92] Gracia C., Woodruff T.K. Oncofertility medical practice: Clinical issues and implementation. New York: Springer; 2012. doi: 10.1007/978-1-4419-9425-7

[93] Gracia C, Woodruff TK. Oncofertility medical practice: Clinical issues and implementation. New York: Springer; 2012. doi: 10.1007/978-1-4419-9425-7

[94] Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43. doi: 10.1016/j.fertnstert.2012.09.028

[95] Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline // Fertil Steril. 2013. Vol. 99, N 1. P. 37–43. doi: 10.1016/j.fertnstert.2012.09.028

[96] Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43. doi: 10.1016/j.fertnstert.2012.09.028

[97] Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–1371. doi: 10.1210/jc.2015-3878

[98] Kim J., Turan V., Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer // J Clin Endocrinol Metab. 2016. Vol. 101, N 4. P. 1364–1371. doi: 10.1210/jc.2015-3878

[99] Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–1371. doi: 10.1210/jc.2015-3878

[100] Bahroudi Z, Zarnaghi MR, Izadpanah M, et al. Review of ovarian tissue cryopreservation techniques for fertility preservation. J Gynecol Obstet Hum Reprod. 2022;51(2):102290. doi: 10.1016/j.jogoh.2021.102290

[101] Bahroudi Z., Zarnaghi M.R., Izadpanah M., et al. Review of ovarian tissue cryopreservation techniques for fertility preservation // J Gynecol Obstet Hum Reprod. 2022. Vol. 51, N 2. P. 102290. doi: 10.1016/j.jogoh.2021.102290

[102] Bahroudi Z, Zarnaghi MR, Izadpanah M, et al. Review of ovarian tissue cryopreservation techniques for fertility preservation. J Gynecol Obstet Hum Reprod. 2022;51(2):102290. doi: 10.1016/j.jogoh.2021.102290

[103] Anderson RA, Hamish BW, Telfer ЕЕ. Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives. Hum Reprod Open. 2017;2017(1):hox001. doi: 10.1093/hropen/hox001. eCollection 2017

[104] Anderson R.A., Hamish B.W., Telfer Е.Е. Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives // Hum Reprod Open. 2017. Vol. 2017, N 1. P. hox001. doi: 10.1093/hropen/hox001

[105] Anderson RA, Hamish BW, Telfer ЕЕ. Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives. Hum Reprod Open. 2017;2017(1):hox001. doi: 10.1093/hropen/hox001. eCollection 2017

[106] Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657–1665. doi: 10.1056/NEJMra1614676

[107] Donnez J., Dolmans M.M. Fertility preservation in women // N Engl J Med. 2017. Vol. 377, N 17. P. 1657–1665. doi: 10.1056/NEJMra1614676

[108] Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657–1665. doi: 10.1056/NEJMra1614676

[109] Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11–24. doi: 10.1007/s10815-012-9912-x

[110] Rosendahl M., Greve T., Andersen C.Y. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature // J Assist Reprod Genet. 2013. Vol. 30, N 1. P. 11–24. doi: 10.1007/s10815-012-9912-x

[111] Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11–24. doi: 10.1007/s10815-012-9912-x

[112] Lapina IA, Dobrokhotova YuE, Sorokin YuA, et al. Preservation of reproductive material using the in vitro maturation method in patients with oncological diseases. Gynecology. 2022;24(1):41–46. EDN: ANHBWK doi: 10.26442/20795696.2022.1.201350

[113] Лапина И.А., Доброхотова Ю.Э., Сорокин Ю.А., и др. Сохранение репродуктивного материала при помощи метода in vitro maturation у пациенток с онкологическими заболеваниями // Гинекология. 2022. Т. 24, № 1. С. 41–46. EDN: ANHBWK doi: 10.26442/20795696.2022.1.201350

[114] Lapina IA, Dobrokhotova YuE, Sorokin YuA, et al. Preservation of reproductive material using the in vitro maturation method in patients with oncological diseases. Gynecology. 2022;24(1):41–46. EDN: ANHBWK doi: 10.26442/20795696.2022.1.201350

[115] Telfer EE, Andersen CY. In vitro growth and maturation of primordial follicles and immature oocytes. Fertil Steril. 2021; 115(5):1116–1125. doi: 10.1016/j.fertnstert.2021.03.004

[116] Telfer E.E., Andersen C.Y. In vitro growth and maturation of primordial follicles and immature oocytes // Fertil Steril. 2021. Vol. 115, N 5. P. 1116–1125. doi: 10.1016/j.fertnstert.2021.03.004

[117] Telfer EE, Andersen CY. In vitro growth and maturation of primordial follicles and immature oocytes. Fertil Steril. 2021; 115(5):1116–1125. doi: 10.1016/j.fertnstert.2021.03.004

RIGHTS & PERMISSIONS

Eco-Vector